Improving treatments for young people with Hodgkin Lymphoma
Official title: Advancing novel therapeutics and translational science to close the survivorship gap in pediatric, adolescent and young adult (AYA) lymphoma
Funded at Emory University · NIH-10782090 · Data updated 2026-11-12
This study is looking for better ways to treat young people with Hodgkin Lymphoma by trying out new therapies and making it easier for them to join clinical trials, all with the hope of helping them live longer and feel better during treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | August 9, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $178,909 |
| NIH project number | 1R50CA285492-01 |
| Project ID | NIH-10782090 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include adolescents and young adults diagnosed with Hodgkin Lymphoma, particularly those who may have limited access to current treatment options.
✕Less likely to help
Patients with other types of cancers or those outside the adolescent and young adult age range may not benefit from this research.
What this research studies
This research focuses on addressing the survival gap in adolescents and young adults (AYA) with Hodgkin Lymphoma by exploring new therapies such as antibody-drug conjugates and immunotherapies. The project aims to enhance access to clinical trials for this age group and develop better treatment strategies that consider individual tumor biology and patient characteristics. By collaborating with national trial networks, the research seeks to incorporate innovative therapies into standard care for both newly diagnosed and relapsed patients. The goal is to improve long-term survival and reduce the side effects associated with traditional chemotherapy and radiation.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less harmful treatments for young patients with Hodgkin Lymphoma.
How similar studies have gone: Previous research has shown promise in using immunotherapy and targeted therapies for Hodgkin Lymphoma, indicating that this approach could be beneficial.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Castellino, Sharon Marie — Emory University
- Study coordinator: Castellino, Sharon Marie
Related research
Other NIH-funded projects on the same topics.
-
Resilience-based program to boost quality of life after lymphoma treatment
A virtual group program called SMART3RP-lymphoma will be offered to lymphoma survivors 0–2 years after finishing treatment to help improve their long-term quality of life.
-
Advancing new therapies to close the survivorship gap for pediatric and young adult lymphoma
A cancer research grant aims to speed up safer, targeted treatments for Hodgkin lymphoma in kids and young adults to improve survival and long-term health.
-
Improving treatments and survivorship for teens and young adults with Hodgkin lymphoma
This effort will bring newer targeted and immune-based therapies to adolescents and young adults with Hodgkin lymphoma to try to improve survival and reduce long-term side effects.
-
Understanding how survivorship care plans affect health outcomes for cancer survivors
A study will look at whether survivorship care plans help reduce deaths and improve health for adults who have survived cancer.
-
Understanding why Black and Hispanic Hodgkin lymphoma patients have worse survival
A patient-centered study to uncover social and care factors that contribute to lower survival among Black and Hispanic people with Hodgkin lymphoma across all ages.
-
Preventing follicular lymphoma progression with precision therapy
This grant tests a targeted approach to stop follicular lymphoma from getting worse or turning into a more aggressive cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.